MATERNUS-KLINIKEN AG (MAK.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:MAK - DE0006044001 - Common Stock
1.07 EUR
+0.04 (+3.88%)
Overall MAK gets a fundamental rating of 1 out of 10. We evaluated MAK against 29 industry peers in the Health Care Providers & Services industry. MAK has a bad profitability rating. Also its financial health evaluation is rather negative. MAK has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
MAK had negative earnings in the past year.
MAK had a positive operating cash flow in the past year.
In the past 5 years MAK always reported negative net income.
MAK had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -9.59%, MAK is not doing good in the industry: 93.10% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.59% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-9.27%
ROA(5y)-6.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of MAK (86.65%) is better than 86.21% of its industry peers.
MAK's Gross Margin has been stable in the last couple of years.
MAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.65% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5Y0.95%
2. Health
2.1 Basic Checks
MAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
MAK has about the same amout of shares outstanding than it did 1 year ago.
MAK has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for MAK is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.98, we must say that MAK is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.98, MAK is not doing good in the industry: 86.21% of the companies in the same industry are doing better.
MAK has a debt to FCF ratio of 19.09. This is a negative value and a sign of low solvency as MAK would need 19.09 years to pay back of all of its debts.
With a Debt to FCF ratio value of 19.09, MAK is not doing good in the industry: 72.41% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.09 | ||
| Altman-Z | -0.98 |
ROIC/WACCN/A
WACC3.97%
2.3 Liquidity
MAK has a Current Ratio of 0.22. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
MAK has a worse Current ratio (0.22) than 89.66% of its industry peers.
A Quick Ratio of 0.21 indicates that MAK may have some problems paying its short term obligations.
MAK's Quick ratio of 0.21 is on the low side compared to the rest of the industry. MAK is outperformed by 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 7.72% over the past year.
Looking at the last year, MAK shows a quite strong growth in Revenue. The Revenue has grown by 11.43% in the last year.
MAK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.73% yearly.
EPS 1Y (TTM)7.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
Revenue 1Y (TTM)11.43%
Revenue growth 3Y0.76%
Revenue growth 5Y-1.73%
Sales Q2Q%3.79%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
MAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MAK indicates a slightly more expensive valuation: MAK is more expensive than 79.31% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MAK indicates a rather cheap valuation: MAK is cheaper than 93.10% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.29 | ||
| EV/EBITDA | 20.1 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for MAK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:MAK (12/8/2025, 7:00:00 PM)
1.07
+0.04 (+3.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners81.7%
Ins Owner ChangeN/A
Market Cap22.44M
Revenue(TTM)114.00M
Net Income(TTM)-13.16M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.2 | ||
| P/FCF | 2.29 | ||
| P/OCF | 2.27 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 20.1 |
EPS(TTM)-0.63
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.47
FCFY43.66%
OCF(TTM)0.47
OCFY44.09%
SpS5.44
BVpS-3.29
TBVpS-3.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.59% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.65% | ||
| FCFM | 8.59% |
ROA(3y)-9.27%
ROA(5y)-6.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.33%
GM growth 5Y0.95%
F-Score4
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.09 | ||
| Debt/EBITDA | 12.53 | ||
| Cap/Depr | 0.79% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 102.07% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.21 | ||
| Altman-Z | -0.98 |
F-Score4
WACC3.97%
ROIC/WACCN/A
Cap/Depr(3y)22.85%
Cap/Depr(5y)18.44%
Cap/Sales(3y)2.27%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.43%
Revenue growth 3Y0.76%
Revenue growth 5Y-1.73%
Sales Q2Q%3.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y595.8%
FCF growth 3Y-3.29%
FCF growth 5Y-1.66%
OCF growth 1Y14887.9%
OCF growth 3Y-4.38%
OCF growth 5Y-1.22%
MATERNUS-KLINIKEN AG / MAK.DE FAQ
Can you provide the ChartMill fundamental rating for MATERNUS-KLINIKEN AG?
ChartMill assigns a fundamental rating of 1 / 10 to MAK.DE.
Can you provide the valuation status for MATERNUS-KLINIKEN AG?
ChartMill assigns a valuation rating of 2 / 10 to MATERNUS-KLINIKEN AG (MAK.DE). This can be considered as Overvalued.
How profitable is MATERNUS-KLINIKEN AG (MAK.DE) stock?
MATERNUS-KLINIKEN AG (MAK.DE) has a profitability rating of 2 / 10.
Can you provide the financial health for MAK stock?
The financial health rating of MATERNUS-KLINIKEN AG (MAK.DE) is 0 / 10.